Sage Therapeutics is a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating disorders of the brain. Read our Community Guidelines: http://bit.ly/2tFyAoj
Location: United States, Massachusetts, Cambridge
Employees: 501-1000
Total raised: $93M
Founded date: 2010
Investors 3
| Date | Name | Website |
| - | Foresite C... | foresiteca... |
| 17.07.2021 | ARCH Ventu... | archventur... |
| - | EcoR1 Capi... | ecor1cap.c... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 13.03.2014 | Series C | $38M | - |
| 16.10.2013 | Series B | $20M | - |
| 18.10.2011 | Series A | $35M | Third Rock... |
Mentions in press and media 23
| Date | Title | Description | Source |
| 06.02.2023 | Biogen and Sage Therapeutics Announce FDA Accepts Filing of ... | Zuranolone is being evaluated as a potential 14-day, rapid-acting, once-daily, oral medication to tr... | einpresswi... |
| 27.10.2021 | Enjoy The Journey: The Need For A Talent Brand | Erin Lanciani, Chief People & Experience Officer, Sage Therapeutics. getty High growth, sc... | forbes.com... |
| 19.10.2021 | 15 Ways Hiring Managers Can Ensure Value Alignment With Pros... | Workplace culture and company values have become an increasingly important job consideration for bot... | forbes.com... |
| 15.06.2021 | Sage Therapeutics and Biogen Announce Positive Pivotal Phase... | At the Day 15 primary endpoint, zuranolone 50 mg showed a statistically significant and clinically m... | marketscre... |
| 17.03.2021 | Sage Therapeutics Announces Continued Positive Zuranolone Da... | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar 17, 2021-- Sage Therapeutics, Inc. (Nasdaq: SAGE) today repo... | oaoa.com/n... |
| 31.12.2020 | Sage Therapeutics, Inc. announced that it has received $649.... | On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company ra... | marketscre... |
| 05.12.2019 | Sage Therapeutics’ stock tanks as Phase III depression study... | Shares of a company developing a drug to treat depression dropped sharply Thursday following the ann... | medcitynew... |
| 31.10.2016 | Third Rock Ventures closes $616 million healthcare fund | Fund IV has not yet begun investing, according to a company representative, but the firm has establi... | medcitynew... |
| 29.06.2016 | The biotech IPO feast flags as investors lose their appeti... | There was a time after the 2008 crash that biotech IPOs were about as popular as snow in March. B... | endpts.com... |
| 13.03.2014 | SAGE Therapeutics Closes $38M in Series C | CAMBRIDGE, MA, Biopharmaceutical company developing novel medicines announced the successful compl... | vcnewsdail... |
Show more